Jun 9, 2026 · 12 min · 12 segments
Thank you to AbbVie for their support on this Medication Review Video Module. In this medication review, Sharon Dudley-Brown, CRNP, PhD from Johns Hopkins University and Angelina Collins, MSN…
Angelina CollinsGuest
Sharon Dudley-BrownHoststudy and help answer some questions regarding the study design and results, and really, most importantly, discuss its relevance to clinical practice.
To refresh everyone's memory, Sequence was a phase 3b multi-center, open-label, efficacy, assessor-blinded, randomized head-to-head trial of recent Kizumab versus Eustekinumab in patients with moderate to severe Crohn's disease who failed one or more anti-TNF agents.
But let's break down what that long sentence that I just reported out to you about the sequence trial.
who was the patient population in this study? So the patient population included those with defined as moderate to severely active Crohn's disease.
They had to have both symptomatic disease activity and symptoms, but they also had to have endoscopically active disease on a centrally red scale.
And so what that means is that the local provider videoed the scope and then sent it to a blinded gastroenterologist to grade it and determine disease activity.
So in this way, all patients had both symptomatic disease activity and they also had endoscopy disease activity as well.
They also and importantly would have failed at least one or more anti-TNF medications.
Sharon, why was it considered open label study or why was it set up to be an open label study?
study and help answer some questions regarding the study design and results, and really, most importantly, discuss its relevance to clinical practice.
To refresh everyone's memory, Sequence was a phase 3b multi-center, open-label, efficacy, assessor-blinded, randomized head-to-head trial of recent Kizumab versus Eustekinumab in patients with moderate to severe Crohn's disease who failed one or more anti-TNF agents.
But let's break down what that long sentence that I just reported out to you about the sequence trial.
who was the patient population in this study? So the patient population included those with defined as moderate to severely active Crohn's disease.
They had to have both symptomatic disease activity and symptoms, but they also had to have endoscopically active disease on a centrally red scale.
And so what that means is that the local provider videoed the scope and then sent it to a blinded gastroenterologist to grade it and determine disease activity.
So in this way, all patients had both symptomatic disease activity and they also had endoscopy disease activity as well.
They also and importantly would have failed at least one or more anti-TNF medications.
Sharon, why was it considered open label study or why was it set up to be an open label study?
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
